vVardis Cuts US IPO Size by More Than 12%

The Swiss dental-treatment company now seeks up to $200 million as it prepares to list on the NYSE.

Updated on Nov. 12, 2026 in Startups

vVardis Cuts US IPO Size by More Than 12%

vVardis, a Zug, Switzerland-based company, reduced the size of its US initial public offering by more than 12%, now offering 8.3 million shares priced between $21 and $24 each. The company originally planned to offer 9.5 million shares and raise up to $228.6 million.

Why it matters

The reduced offering comes as the US IPO market faces pressure amid an AI-led tech selloff and concerns over Nvidia's leadership. Investor sentiment has also been shaped by Democrats' midterm election gains, which fueled fears of strict AI regulation and questions over data center spending.

The revised offering cuts the share count from 9.5 million to 8.3 million, lowering the maximum raise from $228.6 million to $200 million. The final pricing within the $21 to $24 range has not yet been determined.

The players

vVardis

A Zug, Switzerland-based dental technology company founded in 2020 that develops non-invasive treatments for early-stage tooth decay.

Apollo Global Management

A major global alternative asset manager whose funds made a minority investment in vVardis, giving it unicorn status.

Goldman Sachs

A leading global investment bank serving as one of the lead underwriters of the vVardis IPO.

The details

vVardis develops non-invasive dental treatments under its Curodont brand, designed to repair and reverse early-stage tooth decay without drilling or injections. The company was founded in 2020 by Swiss dentists and sisters Haley and Goly Abivardi and achieved unicorn status in April after a minority investment from funds managed by Apollo Global Management. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank and Deutsche Bank Securities are underwriting the IPO.

Timeline

  1. April 2026: vVardis achieves unicorn status after an Apollo-managed fund invests.

  2. Week of November 9, 2026: Anthropic begins its IPO roadshow.

  3. November 12, 2026: vVardis cuts the size of its IPO by more than 12%.

Startups Outlook

The vVardis offering reduction mirrors a broader pattern in which US IPO issuers have trimmed deal sizes amid an AI-led tech selloff and concerns over Nvidia's leadership. Its listing will test whether a non-AI health-tech company can attract investor demand in a market shaped by midterm-driven regulatory fears.

For retail investors, the final pricing within the $21 to $24 range will determine the actual valuation at which shares begin trading on the NYSE under the symbol VVVV. The smaller offering size may affect the depth of shares available at listing.

The takeaway

Reduced IPO sizes often signal that issuers are adjusting to investor demand rather than abandoning a listing. Readers tracking startup listings should watch the final pricing and first-day trading to gauge how the market is receiving non-AI companies.

Further reading

For broader context on early-stage company funding and listings, see Startups.